179 related articles for article (PubMed ID: 28445481)
1. Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells.
Sharma A; Vatapalli R; Abdelfatah E; Wyatt McMahon K; Kerner Z; A Guzzetta A; Singh J; Zahnow C; B Baylin S; Yerram S; Hu Y; Azad N; Ahuja N
PLoS One; 2017; 12(4):e0176139. PubMed ID: 28445481
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
Crea F; Giovannetti E; Cortesi F; Mey V; Nannizzi S; Gallegos Ruiz MI; Ricciardi S; Del Tacca M; Peters GJ; Danesi R
Mol Cancer Ther; 2009 Jul; 8(7):1964-73. PubMed ID: 19531575
[TBL] [Abstract][Full Text] [Related]
3. Correlation between the promoter methylation status of ATP-binding cassette sub-family G member 2 and drug sensitivity in colorectal cancer cell lines.
Moon HH; Kim SH; Ku JL
Oncol Rep; 2016 Jan; 35(1):298-306. PubMed ID: 26497773
[TBL] [Abstract][Full Text] [Related]
4. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.
Signore M; Buccarelli M; Pilozzi E; De Luca G; Cappellari M; Fanciulli M; Goeman F; Melucci E; Biffoni M; Ricci-Vitiani L
Oncotarget; 2016 Jul; 7(28):44113-44128. PubMed ID: 27286453
[TBL] [Abstract][Full Text] [Related]
5. UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients.
Cacciola NA; Calabrese C; Malapelle U; Pellino G; De Stefano A; Sepe R; Sgariglia R; Quintavalle C; Federico A; Bianco A; Uchimura Bastos A; Milone M; Bellevicine C; Milone F; Carlomagno C; Selvaggi F; Troncone G; Fusco A; Pallante P
Mol Carcinog; 2016 May; 55(5):793-807. PubMed ID: 25917796
[TBL] [Abstract][Full Text] [Related]
6. Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo.
Wood JP; Smith AJ; Bowman KJ; Thomas AL; Jones GD
Cancer Med; 2015 Sep; 4(9):1309-21. PubMed ID: 26108357
[TBL] [Abstract][Full Text] [Related]
7. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
Ikehata M; Ogawa M; Yamada Y; Tanaka S; Ueda K; Iwakawa S
Biol Pharm Bull; 2014; 37(1):67-73. PubMed ID: 24172061
[TBL] [Abstract][Full Text] [Related]
8. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
To KK; Leung WW; Ng SS
Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer.
Vendetti FP; Topper M; Huang P; Dobromilskaya I; Easwaran H; Wrangle J; Baylin SB; Poirier JT; Rudin CM
Oncotarget; 2015 Jan; 6(1):56-70. PubMed ID: 25474141
[TBL] [Abstract][Full Text] [Related]
10. Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer.
Miyaki Y; Suzuki K; Koizumi K; Kato T; Saito M; Kamiyama H; Maeda T; Shibata K; Shiya N; Konishi F
Int J Oncol; 2012 Jan; 40(1):217-26. PubMed ID: 21901246
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways.
Moro H; Hattori N; Nakamura Y; Kimura K; Imai T; Maeda M; Yashiro M; Ushijima T
Gastric Cancer; 2020 Jan; 23(1):105-115. PubMed ID: 31555951
[TBL] [Abstract][Full Text] [Related]
12. RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines.
Li XX; Zheng HT; Peng JJ; Huang LY; Shi DB; Liang L; Cai SJ
Int J Clin Exp Pathol; 2014; 7(5):2729-36. PubMed ID: 24966994
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.
Kaneko M; Kotake M; Bando H; Yamada T; Takemura H; Minamoto T
BMC Cancer; 2016 Dec; 16(1):945. PubMed ID: 27955637
[TBL] [Abstract][Full Text] [Related]
14. Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: a novel treatment strategy.
Litvak DA; Bilchik AJ; Cabot MC
J Gastrointest Surg; 2003 Jan; 7(1):140-148. PubMed ID: 12559195
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylated retinoblastoma protein is a potential predictive marker of irinotecan efficacy for colorectal cancer.
Ikai A; Watanabe M; Sowa Y; Kishimoto M; Yanagisawa A; Fujiwara H; Otsuji E; Sakai T
Int J Oncol; 2016 Mar; 48(3):1297-304. PubMed ID: 26783196
[TBL] [Abstract][Full Text] [Related]
16. RhoA regulates resistance to irinotecan by regulating membrane transporter and apoptosis signaling in colorectal cancer.
Ruihua H; Mengyi Z; Chong Z; Meng Q; Xin M; Qiulin T; Feng B; Ming L
Oncotarget; 2016 Dec; 7(52):87136-87146. PubMed ID: 27888624
[TBL] [Abstract][Full Text] [Related]
17. Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF.
Woo JK; Kang JH; Kim B; Park BH; Shin KJ; Song SW; Kim JJ; Kim HM; Lee SJ; Oh SH
Oncotarget; 2015 Sep; 6(27):24047-60. PubMed ID: 26090722
[TBL] [Abstract][Full Text] [Related]
18. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
[TBL] [Abstract][Full Text] [Related]
19. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
20. Weekly High-dose 5-Fluorouracil as 24-hour Infusion Combined with Sodium Folinic Acid (AIO regimen) Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer (CRC).
Wein A; Siebler J; Wolff K; Ostermeier N; Busse D; Hagel A; Koch F; Merx K; Neurath MF; Hofheinz RD
Anticancer Res; 2017 Jul; 37(7):3771-3779. PubMed ID: 28668873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
